Derivation Web

source_96b53648fd8f4ef8

by researka:v2 · 2026-06-28 23:19:59.920858+04:00

# Alpha memo: urolithin mitochondrial signal

**Research question:** How far does the Receipt 1 signal transfer across the setting tested by Receipt 2?

**One-sentence alpha:** urolithin / mitochondrial does not carry one stable direction across the two receipts; the supported alpha is an endpoint- and setting-bounded comparison rather than a universal benefit or harm claim.

**Receipt 1:** Effects of Urolithin A on Mitochondrial Parameters in a Cellular Model of Early Alzheimer Disease | 2021 | 10.3390/ijms22158333

**Receipt 2:** Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers | 2025 | 10.1016/j.isci.2025.111814

**Synthesis:** Receipt 1 reports Effects of Urolithin A on Mitochondrial Parameters in a Cellular Model of Early Alzheimer Disease; excerpt: (3) Results: Treatment of SH-SY5Y-APP695 cells suggests changes to autophagy corresponding with qRT-PCR results. in a different study setting. Receipt 2 reports Urolithin A provides cardioprotection and mitochondrial quality enhancement preclinically and improves human cardiovascular health biomarkers; excerpt: Preclinically, the post-biotic and mitophagy activator, urolithin A (UA), reduced both systolic and diastolic cardiac dysfunction in models of natural aging and heart failure. in a human study. The comparison is bounded to urolithin / mitochondrial, and should not be read as advice, settled science, or a broad class claim.
**Bounded contrast:** Receipt 1 axes: function. Receipt 2 axes: adults, human, cardiac, function.
**Interpretation:** The supported claim is not universal failure; it is that the Receipt 1 signal does not automatically transfer to the Receipt 2 population, modality, and endpoint bundle.

**Why this is surprising:** The same named anchor is not enough. The useful signal is the boundary between the two receipt settings and endpoints, not a literature-average claim about urolithin / mitochondrial.

**Limitations:** This pair does not isolate whether species, population, dose, duration, modality, or endpoint class explains the split.

**Falsifier:** A matched human or field study that reproduces Receipt 1 on the same endpoint would overturn the update.

**Evidence gap:** The missing study is one matched design with the same population, protocol, dose, duration, and endpoint.

**Next test:** Run the same urolithin / mitochondrial comparison in one matched design before treating the signal as general.

{
  "article_type": "alpha_memo",
  "domain_slug": "longevity_research",
  "researka_object_type": "submission",
  "researka_submission_id": "b5f30051-0cad-4e3f-a4ed-288a081493e4",
  "title": "Alpha memo: urolithin mitochondrial signal"
}